سعر جلوبيكسور 37.5 مجم 14 كبسولة 2022

Venlafaxine 37.5 mg capsules, pack of 14; Global Napi Pharmaceuticals (Egypt).

• Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder (US Effexor XR labeling).Population: AdultsDailyMed (U.S. NLM)

• Common adverse reactions include nausea, somnolence, dry mouth, sweating, abnormal ejaculation, anorexia, constipation, erectile dysfunction, and libido decreased.International label, equivalent formulation · DailyMed (U.S. NLM)

• Hypersensitivity to venlafaxine or any component; concomitant use with MAOIs (including linezolid or IV methylene blue) or within 14 days of stopping an MAOI; do not start an MAOI within 7 days of stopping venlafaxine.International label, equivalent formulation · DailyMed (U.S. NLM)

• Boxed warning: antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients; monitor closely.International label, equivalent formulation · DailyMed (U.S. NLM)
• Serotonin syndrome risk with other serotonergic agents; discontinue if suspected. May elevate blood pressure; monitor. Risk of discontinuation syndrome—taper gradually.International label, equivalent formulation · DailyMed (U.S. NLM)

• Available data have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes; third-trimester exposure may be associated with neonatal complications. Consider risks of untreated depression.International label, equivalent formulation · DailyMed (U.S. NLM)
• Venlafaxine and O-desmethylvenlafaxine are present in human milk; consider developmental benefits of breastfeeding against clinical need and potential adverse effects.International label, equivalent formulation · DailyMed (U.S. NLM)

• Venlafaxine: Potent inhibitor of neuronal serotonin and norepinephrine reuptake; weak dopamine reuptake inhibitor.